Tabalumab: Development discontinued

Eli Lilly discontinued development of tabalumab to treat SLE due to insufficient efficacy in the double-blind, placebo-controlled, international Phase III ILLUMINATE 1 and ILLUMINATE 2 trials in the indication. In ILLUMINATE 1, both doses of subcutaneous tabalumab missed the primary endpoint of improving the SRI-5 rate at week 52 vs. placebo. In ILLUMINATE 2, Lilly said the higher dose of tabalumab met the same primary endpoint vs. placebo. The pharma declined to disclose details, but said the decision was not based on safety concerns. ...